Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Share-based Compensation (2016 - 2025)

Regenxbio (RGNX) has 12 years of Share-based Compensation data on record, last reported at $8.4 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 12.23% year-over-year to $8.4 million; the TTM value through Dec 2025 reached $34.6 million, down 10.14%, while the annual FY2025 figure was $34.6 million, 10.14% down from the prior year.
  • Share-based Compensation reached $8.4 million in Q4 2025 per RGNX's latest filing, down from $9.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $11.2 million in Q1 2023 and bottomed at $8.3 million in Q4 2023.
  • Average Share-based Compensation over 5 years is $9.6 million, with a median of $9.7 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: rose 23.74% in 2021, then fell 14.31% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $9.2 million in 2021, then increased by 2.69% to $9.4 million in 2022, then dropped by 11.37% to $8.3 million in 2023, then increased by 14.44% to $9.5 million in 2024, then decreased by 12.23% to $8.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $8.4 million in Q4 2025, $9.0 million in Q3 2025, and $8.7 million in Q2 2025.